Drug intelligence / Profile preview

plutavimab

Development stage: Discontinued
Lead developer: Sorrento Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Intranasal

Overview

Plutavimab (COVI-AMG, STI-2020) is a monoclonal antibody developed for the treatment of COVID-19. It was engineered for ultra-high potency and designed to neutralize SARS-CoV-2 by targeting its spike glycoprotein (S protein), thereby preventing viral entry into host cells. The antibody demonstrated strong neutralizing activity against multiple SARS-CoV-2 variants in preclinical studies and was intended for intravenous administration with a low effective dose suitable for outpatient use. Plutavimab was developed by Sorrento Therapeutics and advanced through Phase 1 and Phase 2 clinical trials before being discontinued[3][4][7].

Brand names: COVI-AMG
Other names: plutavimabCOVI-AMGSTI-2020STI2020STI 2020

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on plutavimab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on plutavimab.

Explore the full profile